It's also controversial. Sarepta is the first company to ask the FDA to give a gene therapy accelerated approval, based on preliminary evidence. In documents released Wednesday, FDA reviewers concluded Sarepta's clinical trials " do not provide unambiguous evidence " that the therapy, known as SRP-9001, is "likely beneficial for ambulatory patients" with Duchenne. The agency also raised some safety concerns.